首页> 外文期刊>Science Signaling >SILAC identifies LAD1 as a filamin-binding regulator of actin dynamics in response to EGF and a marker of aggressive breast tumors
【24h】

SILAC identifies LAD1 as a filamin-binding regulator of actin dynamics in response to EGF and a marker of aggressive breast tumors

机译:Silac鉴定Lad1作为肌动蛋白动态的菲素结合调节剂,响应EGF和侵袭性乳腺肿瘤的标志物

获取原文
获取原文并翻译 | 示例
           

摘要

Mutations mimicking growth factor-induced proliferation and motility characterize aggressive subtypes of mammary tumors. To unravel currently unknown players in these processes, we performed phosphoproteomic analysis on untransformed mammary epithelial cells (MCF10A) that were stimulated in culture with epidermal growth factor (EGF). We identified ladinin-1 (LAD1), a largely uncharacterized protein to date, as a phosphorylation-regulated mediator of the EGF-to-ERK pathway. Further experiments revealed that LAD1 mediated the proliferation and migration of mammary cells. LAD1 was transcriptionally induced, phosphorylated, and partly colocalized with actin stress fibers in response to EGF. Yeast two-hybrid, proximity ligation, and coimmunoprecipitation assays revealed that LAD1 bound to actin-cross-linking proteins called filamins. Cosedimentation analyses indicated that LAD1 played a role in actin dynamics, probably in collaboration with the scaffold protein 14-3-3. (also called SFN). Depletion of LAD1 decreased the expression of transcripts associated with cell survival and inhibited the growth of mammary xenografts in an animal model. Furthermore, LAD1 predicts poor patient prognosis and is highly expressed in aggressive subtypes of breast cancer characterized as integrative clusters 5 and 10, which partly correspond to triple-negative and HER2-positive tumors. Thus, these findings reveal a cytoskeletal component that is critically involved in cell migration and the acquisition of oncogenic attributes in human mammary tumors.
机译:模仿生长因子诱导的增殖和动力表征乳腺癌的侵袭性亚型的突变。为了在这些过程中解开目前未知的玩家,我们对具有表皮生长因子(EGF)培养的未转化乳腺上皮细胞(MCF10A)进行了磷肝蛋白酶分析。我们鉴定了Ladinin-1(LAD1),迄今为止是迄今为止的磷酸化调节介质的磷酸化介质。进一步的实验表明,Lad1介导乳腺细胞的增殖和迁移。响应于EGF,通过肌动蛋白应激纤维转录,磷酸化和部分地分解LAD1,并将其部分地与EGF的致粘蛋白应激纤维分开。酵母双杂交,邻近结扎和辅助连接和CoImMunoprecipation测定显示Lad1结合到称为亚胺蛋白的肌动蛋白交联蛋白。提出的分析表明,Lad1在actin动态中发挥了作用,可能与支架蛋白质14-3-3合作。 (也称为SFN)。 Lad1的耗尽降低了与细胞存活相关的转录物的表达,并抑制动物模型中乳腺异种移植物的生长。此外,Lad1预测患者预后差,并且在乳腺癌的侵略性亚型中表达,其特征为综合簇5和10,其部分对应于三阴性和HER2阳性肿瘤。因此,这些发现揭示了一种细胞骨架组分,其批判性地参与细胞迁移和致癌物质的致癌物质。

著录项

  • 来源
    《Science Signaling》 |2018年第515期|共14页
  • 作者单位

    Weizmann Inst Sci Dept Biol Regulat IL-76100 Rehovot Israel;

    Weizmann Inst Sci Dept Biol Regulat IL-76100 Rehovot Israel;

    Weizmann Inst Sci Dept Biol Regulat IL-76100 Rehovot Israel;

    Weizmann Inst Sci Dept Biol Regulat IL-76100 Rehovot Israel;

    Weizmann Inst Sci Dept Phys Complex Syst IL-76100 Rehovot Israel;

    Weizmann Inst Sci Dept Biol Regulat IL-76100 Rehovot Israel;

    Weizmann Inst Sci Dept Biol Regulat IL-76100 Rehovot Israel;

    Weizmann Inst Sci Dept Biol Regulat IL-76100 Rehovot Israel;

    Weizmann Inst Sci Dept Biol Regulat IL-76100 Rehovot Israel;

    Weizmann Inst Sci Dept Biol Regulat IL-76100 Rehovot Israel;

    Weizmann Inst Sci Dept Biol Regulat IL-76100 Rehovot Israel;

    Weizmann Inst Sci Dept Biol Regulat IL-76100 Rehovot Israel;

    Weizmann Inst Sci Dept Biol Regulat IL-76100 Rehovot Israel;

    Weizmann Inst Sci Dept Biol Regulat IL-76100 Rehovot Israel;

    Technion Dept Biol Smoler Prot Ctr IL-32000 Haifa Israel;

    Univ Cambridge Canc Res UK Cambridge Inst Cambridge CB2 2XZ England;

    Weizmann Inst Sci Dept Biol Regulat IL-76100 Rehovot Israel;

    Hebrew Univ Jerusalem Hadassah Med Sch Dept Immunol &

    Canc Res IL-91010 Jerusalem Israel;

    Technion Dept Biol Smoler Prot Ctr IL-32000 Haifa Israel;

    Univ Cambridge Canc Res UK Cambridge Inst Cambridge CB2 2XZ England;

    Weizmann Inst Sci Dept Biol Regulat IL-76100 Rehovot Israel;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 细胞生物学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号